These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25650898)

  • 1. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades.
    Lazar L; Lebenthal Y; Yackobovitch-Gavan M; Shalitin S; de Vries L; Phillip M; Meyerovitch J
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1445-51. PubMed ID: 25650898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades.
    Lazar L; Meyerovitch J; de Vries L; Phillip M; Lebenthal Y
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):570-6. PubMed ID: 24033561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual cycle, reproductive function, body mass index, and metabolic profiles of women with former central precocious puberty: 10-20-year longitudinal cohort study in southern Thailand.
    Satitpatanapan P; Jaruratanasirikul S; Sriplung H
    J Pediatr Endocrinol Metab; 2020 Jul; 33(7):933-940. PubMed ID: 32623380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Patients with Central Precocious Puberty Due to Loss-of-Function Mutations in the MKRN3 Gene after Treatment with Gonadotropin-Releasing Hormone Analog.
    Ramos CO; Macedo DB; Canton APM; Cunha-Silva M; Antonini SRR; Stecchini MF; Seraphim CE; Rodrigues T; Mendonca BB; Latronico AC; Brito VN
    Neuroendocrinology; 2020; 110(7-8):705-713. PubMed ID: 31671431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents.
    Iannetta R; Melo AS; Iannetta O; Marchini JS; Paula FJ; Martinelli CE; Rosa e Silva AC; Ferriani RA; Martins WP; Reis RM
    J Pediatr Adolesc Gynecol; 2015 Oct; 28(5):304-8. PubMed ID: 26081481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near final adult height, and body mass index in overweight/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs.
    Sinthuprasith P; Dejkhamron P; Wejaphikul K; Unachak K
    J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1369-1375. PubMed ID: 31605579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Patients with Central Precocious Puberty due to Hypothalamic Hamartoma after GnRHa Treatment: Anthropometric, Metabolic, and Reproductive Aspects.
    Ramos CO; Latronico AC; Cukier P; Macedo DB; Bessa DS; Cunha-Silva M; Arnhold IJ; Mendonca BB; Brito VN
    Neuroendocrinology; 2018; 106(3):203-210. PubMed ID: 28558376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
    Magiakou MA; Manousaki D; Papadaki M; Hadjidakis D; Levidou G; Vakaki M; Papaefstathiou A; Lalioti N; Kanaka-Gantenbein C; Piaditis G; Chrousos GP; Dacou-Voutetakis C
    J Clin Endocrinol Metab; 2010 Jan; 95(1):109-17. PubMed ID: 19897682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty.
    Arcari AJ; Freire AV; Escobar ME; Ballerini MG; Ropelato MG; Bergadá I; Gryngarten MG
    J Pediatr Endocrinol Metab; 2019 Feb; 32(2):181-186. PubMed ID: 30699070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life.
    Loochi SA; Demol S; Nagelberg N; Lebenthal Y; Phillip M; Yackobovitch-Gavan M
    J Pediatr Endocrinol Metab; 2021 Mar; 34(3):373-383. PubMed ID: 33609438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Idiopathic central precocious puberty in girls in Bahia, Brazil].
    Aguiar AL; Couto-Silva AC; Freitas I; Cruz T; Rodrigues M; Adan LF
    Arq Bras Endocrinol Metabol; 2005 Aug; 49(4):536-41. PubMed ID: 16358082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty.
    Arrigo T; De Luca F; Antoniazzi F; Galluzzi F; Segni M; Rosano M; Messina MF; Lombardo F
    Eur J Endocrinol; 2004 Apr; 150(4):533-7. PubMed ID: 15080784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Body Mass Index in Girls with Idiopathic Central Precocious Puberty under Gonadotropin-Releasing Hormone Analogue Therapy: The Spanish Registry.
    Corripio R; Soriano-Guillén L; Herrero FJ; Cañete R; Castro-Feijoó L; Escribano A; Espino R; Labarta JI; Argente J
    Horm Res Paediatr; 2016; 86(3):154-160. PubMed ID: 27529349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
    Sørensen K; Andersson AM; Skakkebaek NE; Juul A
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
    Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
    J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of GnRH analog therapy on body mass in central precocious puberty.
    Głab E; Barg E; Wikiera B; Grabowski M; Noczyńska A
    Pediatr Endocrinol Diabetes Metab; 2009; 15(1):7-11. PubMed ID: 19454183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty.
    Swaiss HH; Khawaja NM; Farahid OH; Batieha AM; Ajlouni KM
    Saudi Med J; 2017 Nov; 38(11):1101-1107. PubMed ID: 29114697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.